A carregar...
Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada
IMPORTANCE: Tisagenlecleucel, a chimeric antigen receptor T-cell therapy for relapsed or refractory pediatric acute lymphoblastic leukemia, has been approved for use in multiple jurisdictions. The public list price is US $475 000, or more than CaD $600 000. Assessing the cost-effectiveness of tisage...
Na minha lista:
| Publicado no: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6990832/ https://ncbi.nlm.nih.gov/pubmed/31971547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.5909 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|